Compare Sony Group Corp (SONY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs 10X Genomics Inc — how do they compare? Sony Group Corp trades at $23.57 (market cap $138.72B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: Sony Group Corp is far larger — about 16.2× 10X Genomics Inc's market cap, and Sony Group Corp pays a 0.67% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SONY | TXG | |
|---|---|---|
Market Cap | $138.72B | $8.55B |
Sector | Technology | Health |
52-Week High | $30.26 | $67.29 |
52-Week Low | $19.32 | $11.34 |
Enterprise Value | $136.57B | $8.08B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $23.53, down 4.19% over 24 hours amid bearish technical signals. The company maintains strong operational cash flow of $2.32 trillion for 2025 and has beaten earnings expectations in two of the last three quarters. Analyst consensus remains bullish with 11 buy ratings versus 5 holds, though recent news highlights Sony's legal actions against Anthropic for copyright infringement and strategic focus on organic expansion over large-scale acquisitions.
The outlook is mixed: solid fundamentals and analyst support suggest long-term value, but near-term technical weakness and a projected net income decline to -$221.6 billion for 2026 pose risks. Investment opportunity lies in Sony's diversified entertainment ecosystem and content moat, while key risks include execution on profitability targets and competitive pressures in streaming and gaming.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
